290 related articles for article (PubMed ID: 21156288)
1. Non-stem cell origin for oligodendroglioma.
Persson AI; Petritsch C; Swartling FJ; Itsara M; Sim FJ; Auvergne R; Goldenberg DD; Vandenberg SR; Nguyen KN; Yakovenko S; Ayers-Ringler J; Nishiyama A; Stallcup WB; Berger MS; Bergers G; McKnight TR; Goldman SA; Weiss WA
Cancer Cell; 2010 Dec; 18(6):669-82. PubMed ID: 21156288
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells.
Lindberg N; Jiang Y; Xie Y; Bolouri H; Kastemar M; Olofsson T; Holland EC; Uhrbom L
J Neurosci; 2014 Oct; 34(44):14644-51. PubMed ID: 25355217
[TBL] [Abstract][Full Text] [Related]
3. Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors.
Ahmad ST; Rogers AD; Chen MJ; Dixit R; Adnani L; Frankiw LS; Lawn SO; Blough MD; Alshehri M; Wu W; Marra MA; Robbins SM; Cairncross JG; Schuurmans C; Chan JA
Nat Commun; 2019 May; 10(1):2000. PubMed ID: 31043608
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analyses of neural stem cell lineage markers in normal feline brains and glial tumors.
Yoshida K; Chambers JK; Nibe K; Kagawa Y; Uchida K
Vet Pathol; 2024 Jan; 61(1):46-57. PubMed ID: 37358305
[TBL] [Abstract][Full Text] [Related]
5. [Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis].
Kondo T
Brain Nerve; 2009 Jul; 61(7):741-51. PubMed ID: 19618851
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of neural stem cell lineage markers in canine brains, gliomas, and a glioma cell line.
Yoshida K; Chambers JK; Uchida K
Vet Pathol; 2023 Jan; 60(1):35-46. PubMed ID: 36384382
[TBL] [Abstract][Full Text] [Related]
7. NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis.
Briançon-Marjollet A; Balenci L; Fernandez M; Estève F; Honnorat J; Farion R; Beaumont M; Barbier E; Rémy C; Baudier J
Carcinogenesis; 2010 Oct; 31(10):1718-25. PubMed ID: 20651032
[TBL] [Abstract][Full Text] [Related]
8. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Lamoral-Theys D; Le Mercier M; Le Calvé B; Rynkowski MA; Bruyère C; Decaestecker C; Haibe-Kains B; Bontempi G; Dubois J; Lefranc F; Kiss R
Neoplasia; 2010 Jan; 12(1):69-79. PubMed ID: 20072655
[TBL] [Abstract][Full Text] [Related]
9. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
Hide T; Takezaki T; Nakatani Y; Nakamura H; Kuratsu J; Kondo T
Stem Cells; 2011 Apr; 29(4):590-9. PubMed ID: 21360625
[TBL] [Abstract][Full Text] [Related]
10. Mosaic analysis with double markers reveals tumor cell of origin in glioma.
Liu C; Sage JC; Miller MR; Verhaak RG; Hippenmeyer S; Vogel H; Foreman O; Bronson RT; Nishiyama A; Luo L; Zong H
Cell; 2011 Jul; 146(2):209-21. PubMed ID: 21737130
[TBL] [Abstract][Full Text] [Related]
11. High-grade glioma relationship to the neural stem cell compartment: a retrospective review of 104 cases.
Marsh JC; Wendt JA; Herskovic AM; Diaz A; Gielda BT; Byrne RW
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e159-65. PubMed ID: 21592679
[TBL] [Abstract][Full Text] [Related]
12. p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.
Gonzalez PP; Kim J; Galvao RP; Cruickshanks N; Abounader R; Zong H
Glia; 2018 May; 66(5):999-1015. PubMed ID: 29392777
[TBL] [Abstract][Full Text] [Related]
13. Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.
Ledur PF; Liu C; He H; Harris AR; Minussi DC; Zhou HY; Shaffrey ME; Asthagiri A; Lopes MB; Schiff D; Lu YC; Mandell JW; Lenz G; Zong H
Neuro Oncol; 2016 Oct; 18(10):1413-24. PubMed ID: 27106408
[TBL] [Abstract][Full Text] [Related]
14. Expression of Oligodendrocyte Precursor Cell Markers in Canine Oligodendrogliomas.
Kishimoto TE; Uchida K; Thongtharb A; Shibato T; Chambers JK; Nibe K; Kagawa Y; Nakayama H
Vet Pathol; 2018 Sep; 55(5):634-644. PubMed ID: 29852819
[TBL] [Abstract][Full Text] [Related]
15. Oligodendrocyte/type-2 astrocyte progenitor cells and glial-restricted precursor cells generate different tumor phenotypes in response to the identical oncogenes.
Wang J; Bushman J; Wang X; Mayer-Proschel M; Johnson M; Noble M
J Neurosci; 2013 Oct; 33(42):16805-17. PubMed ID: 24133281
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Hernandez-Lain A; Hilario A; Sepulveda JM; Cantero D; Ramos A; Perez-Nuñez A
Neurology; 2016 Jul; 87(1):114-5. PubMed ID: 27251883
[No Abstract] [Full Text] [Related]
17. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
[TBL] [Abstract][Full Text] [Related]
18. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Silber J; Lim DA; Petritsch C; Persson AI; Maunakea AK; Yu M; Vandenberg SR; Ginzinger DG; James CD; Costello JF; Bergers G; Weiss WA; Alvarez-Buylla A; Hodgson JG
BMC Med; 2008 Jun; 6():14. PubMed ID: 18577219
[TBL] [Abstract][Full Text] [Related]
19. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications.
Perry A; Scheithauer BW; Macaulay RJ; Raffel C; Roth KA; Kros JM
J Neuropathol Exp Neurol; 2002 Nov; 61(11):947-55. PubMed ID: 12430711
[TBL] [Abstract][Full Text] [Related]
20. Primitive Oligodendrocyte Precursor Cells Are Highly Susceptible to Gliomagenic Transformation.
Zamler DB; Hu J
Cancer Res; 2023 Mar; 83(6):807-808. PubMed ID: 36919423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
